Opus Genetics IRD Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period at other companies
Other financials
Where this comes from
Reported directly by Opus Genetics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod.
The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Opus Genetics's share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Opus Genetics's share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period?
- Opus Genetics (IRD) reported share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period of 0 in Q1 2026.
- What does share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period mean?
- The total number of equity instruments, excluding options, that were forfeited by employees or service providers during the period due to failure to meet vesting conditions. High forfeiture rates may indicate high employee turnover or aggressive performance targets. This metric helps adjust the expected future expense of share-based compensation.